BPC-157

What it is

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — based on a partial sequence of a protective protein found in human gastric juice. It's also known as Body Protection Compound-157, and it has never been developed into, or approved as, a branded pharmaceutical product by any regulatory agency in the world.

Over the past decade it has become one of the most talked-about compounds in underground sports medicine, longevity, and bodybuilding circles, primarily for tendon and ligament injuries, joint pain, and gut-related complaints. That popularity rests almost entirely on an impressive body of rodent research and enthusiastic clinical anecdote, not on large human trials. The single most important fact to understand about BPC-157 is the size of the gap between its animal data and its human data — and that gap should shape how any claim about it is read.

BPC-157 has no trade name. It's typically compounded and dispensed under its generic peptide name, most often as an injectable solution.

How it works

Preclinical research suggests BPC-157 acts through several overlapping cell-signaling pathways rather than a single, well-defined receptor mechanism. It appears to activate VEGFR2 (vascular endothelial growth factor receptor 2) and to promote nitric oxide synthesis through the Akt–eNOS axis — both of which drive angiogenesis, or new blood vessel formation. This is the leading proposed explanation for BPC-157's reported healing effects in poorly vascularized tissue such as tendons and myotendinous junctions.¹

It also appears to engage ERK1/2 signaling, a pathway tied to cell proliferation and survival, and shows anti-inflammatory activity and support of fibroblast function in animal tissue-repair models.¹ A separate, older line of rodent literature — not covered in the most recent formal review, but frequently cited in the broader preclinical corpus — has also proposed effects on the gut–brain axis and on dopaminergic and serotonergic signaling, based largely on gastric ulcer-healing models.

Human pharmacokinetic data are essentially nonexistent. The only relevant figures come from a single small pilot study of intravenous BPC-157 given to two healthy adults at doses up to 20 mg, which reported no adverse effects on cardiac, hepatic, renal, or thyroid biomarkers — far too small a dataset to establish a reliable half-life, distribution, or clearance profile in humans. In animal studies, BPC-157 has been given orally (it's unusually stable in gastric juice for a peptide), subcutaneously, and intraperitoneally; in human off-label use it's most often injected subcutaneously, intramuscularly, or directly into a joint, though oral capsule versions are also sold without established human absorption data.

What the research shows

Animal / preclinical evidence

The originating research group at the University of Zagreb, led by Predrag Sikiric, has published extensively since the 1990s on BPC-157 in rodent models of gastric ulcers, inflammatory bowel disease, tendon and ligament injury, spinal cord injury, and general wound healing.¹ This body of work is large and mechanistically consistent, showing benefits attributed to angiogenesis promotion and anti-inflammatory activity — but it has not been followed by a large-scale human trial from this or any other group.

Human evidence

The human evidence for BPC-157 is thin, and this should be stated plainly before any discussion of its reported effects. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine — the most current and authoritative synthesis available — identified only three small human pilot studies in the entire published record, confirmed no adverse effects were reported in any of them, and concluded that BPC-157 "should be considered investigational," calling for well-designed human trials.¹

The largest of the three is a retrospective chart review of 17 patients with chronic knee pain treated with intra-articular BPC-157 (4 mg per injection) at a single Florida clinic, with 16 reachable for follow-up.² Of 12 patients who received BPC-157 alone, 11 (91.6%) reported significant improvement, and 7 reported relief lasting more than six months. But the study had no placebo control, no randomization, no standardized outcome measures — pain was assessed by phone call rather than a validated instrument — and the same physician who gave the injections also collected the outcome data. These are significant limitations that prevent any causal conclusion.

A second small, uncontrolled pilot examined BPC-157's effect on interstitial cystitis symptoms, again without randomization, blinding, or a placebo comparator. The third is the tiny intravenous safety pilot described above (2 subjects). Across all three studies combined, the entire human evidence base for BPC-157 totals roughly 30 subjects.

FDA's own scientific staff reached a similarly cautious conclusion in a July 2026 briefing document prepared for the Pharmacy Compounding Advisory Committee (PCAC), stating that the evidence "is wholly insufficient to support a finding that BPC-157 is safe and effective... for any human indication," and formally recommending against including BPC-157 on the 503A Bulks List — a recommendation the PCAC itself voted to override, 8–6.⁵ No orthopedic or sports-medicine society has issued a clinical practice guideline endorsing BPC-157 for any indication.

Bottom line: BPC-157's reputation for tendon, ligament, and gut-related recovery rests almost entirely on rodent data and clinical anecdote. The human evidence — three small, uncontrolled pilot studies — does not meet the bar of a randomized, placebo-controlled trial, and patients should understand this distinction clearly before deciding whether it fits their care.

Typical use and dosing

No dose-ranging study has established an optimal or maximal human dose for BPC-157. What exists in the literature and in clinical practice falls into three distinct tiers that should not be conflated:

When BPC-157 is prescribed following a physician's clinical evaluation, dosing is individualized based on indication, patient history, and clinical judgment — not derived from a standardized, trial-validated protocol, because no such protocol currently exists in the peer-reviewed literature.

Safety, side effects, and who should avoid it

In the small human pilot studies, no adverse effects were reported — but sample sizes of 17, an unspecified small number, and 2 are far too small to detect anything but the most common side effects, and cannot rule out rare or long-term safety signals. No study has followed human BPC-157 users for safety over a period of months to years in a controlled way.

The FDA's original 2023 rationale for restricting BPC-157 cited potential immunogenicity — the risk that the immune system could react to a synthetic peptide, particularly with certain administration routes — along with concerns about peptide-related manufacturing impurities (truncated sequences, residual solvents, racemized amino acids) and API characterization complexities. These are concerns about the drug product and manufacturing process as much as about BPC-157's underlying biology.³

Because BPC-157 spent most of 2023 through early 2026 unable to be legally compounded, a meaningful share of the product circulating outside licensed medical channels has come from unregulated "research chemical" vendors rather than licensed pharmacies — which materially raises the risk of contamination, mislabeling, or inaccurate concentration, independent of the peptide's own biology. Pregnancy, lactation, active or suspected malignancy, and known hypersensitivity are treated as contraindications.

Regulatory status

This section reflects the situation as of publication (late July 2026) and is changing quickly — treat it as a snapshot, not a permanent determination. BPC-157 is not FDA-approved for any indication in the United States, and no specialty medical society has issued a clinical guideline endorsing its use.

In September 2023, FDA placed BPC-157 into Category 2 of its interim 503A/503B bulk drug substances policy — the category reserved for substances the agency judged to pose "significant safety risks" — which meant licensed compounding pharmacies could not legally prepare it.³ That restriction held through most of 2023–2025.

The picture began shifting in 2026. On February 27, HHS Secretary Robert F. Kennedy Jr. announced intent to move roughly 14 of the 19 originally restricted Category 2 peptides, including BPC-157, back toward legal compounding status. On April 15–16, FDA formally removed BPC-157 from the Category 2 list, effective April 23, 2026 — which referred it to the Pharmacy Compounding Advisory Committee (PCAC) for scientific review, rather than approving it outright.⁶ On July 23, 2026, the PCAC voted 8–6 (with one abstention) to recommend BPC-157 for inclusion on the 503A Bulks List — overriding FDA's own scientific staff, who had recommended against inclusion in their briefing document that same month.⁵⁷

Removal from Category 2 and a PCAC recommendation are not the same as final approval. As of this writing, BPC-157 has not completed FDA rulemaking to be formally added to the 503A Bulks List, and industry analysts project the process could extend into 2027. Aurafil confirms current FDA status on an ongoing basis and only dispenses BPC-157 pursuant to a valid prescription following individualized clinical evaluation.

BPC-157 is explicitly named on the World Anti-Doping Agency's 2026 Prohibited List and is banned at all times, in and out of competition.⁹

Frequently asked questions